41538-36-7

Basic information

• Product Name: 4-(4-FLUOROBENZOYL)PYRIDINE
• Synonyms: (4-Fluorophenyl)pyridin-4-ylmethanone;4-(4-Fluorobenzoyl)pyridine, 1-Fluoro-4-[(pyridin-4-yl)carbonyl]benzene
• CAS NO: 41538-36-7
• Molecular Formula: C₁₂H₈FNO
• Molecular Weight: 201.2
• Mol File: 41538-36-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 85-87°C
• Boiling Point: 326.1°C at 760 mmHg
• Flash Point: 151°C
• Appearance: /
• Density: 1.219g/cm³
• Vapor Pressure: 0.00022mmHg at 25°C
• Refractive Index: 1.57
• CAS DataBase Reference: 4-(4-FLUOROBENZOYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-FLUOROBENZOYL)PYRIDINE(41538-36-7)
• EPA Substance Registry System: 4-(4-FLUOROBENZOYL)PYRIDINE(41538-36-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 41538-36-7(Hazardous Substances Data)

Usage

Description

4-(4-FLUOROBENZOYL)PYRIDINE is an organic compound with the molecular formula C11H8FNO. It is a derivative of pyridine, featuring a benzoyl group with a fluorine atom substitution at the para position. 4-(4-FLUOROBENZOYL)PYRIDINE has potential applications in the pharmaceutical industry due to its unique chemical structure and properties.

Uses

Used in Pharmaceutical Industry:
4-(4-FLUOROBENZOYL)PYRIDINE is used as an active pharmaceutical ingredient for increasing cardiac contractility and treating congestive heart failure. Its application is based on its ability to enhance the strength of heart muscle contractions, which can improve the pumping efficiency of the heart and alleviate symptoms associated with heart failure.
Additionally, 4-(4-FLUOROBENZOYL)PYRIDINE is utilized in the development of pharmaceutical compositions, which are formulations designed to deliver the compound in a controlled and effective manner. These compositions may include various excipients, such as fillers, binders, and stabilizers, to ensure the compound's stability, bioavailability, and targeted delivery to the site of action.
Furthermore, 4-(4-FLUOROBENZOYL)PYRIDINE is involved in the preparation of pharmaceutical compositions, which involves a series of chemical reactions and processes to synthesize the desired compound with the required purity and quality. This preparation process is crucial for ensuring the safety, efficacy, and consistency of the final product.

InChI:InChI=1/C12H8FNO/c13-11-3-1-9(2-4-11)12(15)10-5-7-14-8-6-10/h1-8H

Upstream product

• 39178-35-3 isonicotinoyl chloride hydrochloride 
• 108-89-4 picoline 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 732286-45-2 4-[(4-fluorophenyl)methyl]pyridine 
• 587-78-0 1-(4-fluorobenzyl)pyridin-1-ium bromide 

Downstream Products

• 71859-16-0 4-[2-(4-fluoro-phenyl)-[1,3]dioxolan-2-yl]-pyridine 
• 96835-26-6 (4-chlorophenyl)-(4-fluorophenyl)-(4-pyridyl) methanol 
• 54924-33-3 α-(4-fluorophenyl)-4-piperidinemethanol 
• 117023-91-3 α,β-bis(4-fluorophenyl)-α-4-pyridineethanol 
• 131911-99-4 α-cyclohexyl-α-(4-fluorophenyl)-4-pyridinemethanol 
• 92822-03-2 4-(4-fluorobenzyl)piperidine hydrochloride 
• 117023-26-4 1-[4-(3-{4-[1,2-Bis-(4-fluoro-phenyl)-1-hydroxy-ethyl]-piperidin-1-yl}-propoxy)-3-methoxy-phenyl]-ethanone 
• 117022-58-9 1,2-Bis-(4-fluoro-phenyl)-1-piperidin-4-yl-ethanol 
• 96835-07-3 (4-Chloro-phenyl)-(4-fluoro-phenyl)-(1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-methanol 
• 96835-31-3 4-[(4-Chloro-phenyl)-(4-fluoro-phenyl)-hydroxy-methyl]-1-methyl-pyridinium; iodide 
• 96835-52-8 4-[1-(4-Chloro-phenyl)-1-(4-fluoro-phenyl)-meth-(E)-ylidene]-1-methyl-piperidin-3-ol 
• 92822-02-1 4-(4-fluorobenzyl)piperidine 
• 131912-01-1 4-[(Cyclohexyl)(4-fluorophenyl)methyl]piperidine 
• 131912-00-0 4-[(cyclohexyl)(4-fluorophenyl)methyl]pyridine 

Relevant articles and documents

Photocatalyst-controlled and visible light-enabled selective oxidation of pyridinium salts

This study proposes two different methods of photocatalytic-controlled and visible light-induced selective oxidation of pyridiniums with air as the terminal oxidant. The key to these transformations is to choose the appropriate light source and photocatal

Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment

A method of inhibiting Type 1 allergic responses in a living animal body with substituted heterocyclic amines is disclosed wherein the active agents are expressed generally by the formula which includes certain known and certain known compounds: STR1 wherein P is zero, one or two; m is one to six inclusive; A is selected from hydrogen, hydroxy or cyano; d is zero or one; Q is --CH--, CH2 -- or STR2 n is zero or one and when Q is --CH-- and n is one, a double bond is formed with one of the adjacent carbons but not both at the same time, and when n and d are zero at the same time, a double bond is formed between the α carbon and a carbon of the central heterocyclic amine ring; Ar, D and R are selected from phenyl, substituted phenyl, pyridinyl, thienyl, furanyl or naphthyl and in addition, R may have the values benzyl, substituted benzyl, cycloalkyl or loweralkyl and D may additionally have the values: 2H-1-benzopyran-2-one,4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 2,3-dihydro-4H-1-benzopyran-4-one, 1,4-benzodioxanloweralkyl-2-yl or 1,1'-biphenyl-4-yl and the pharmaceutically acceptable salts thereof.

1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives

Novel 1-[(heterocyclyl)alkyl]-4-diarylmethoxy piperidine derivatives are disclosed having the formula STR1 where n is 2-6, Ar1 and Ar2 are aryl and B is a substituted benzimidazolyl radical. These compounds are useful for their antianaphylactic and antihistaminic properties. Specific claimed compounds are 1-{3-[4-(diphenylmethoxy)-1-piperidinyl]-propyl}-1,3-dihydro-2H-benzimidazol-2-one, 1-{2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl}1-, 3-dihydro-2H-benzimidazol-2-one, and 1-{4-[4-(diphenylmethoxy)-1-piperidinyl]butyl}-1,3-dihydro-2H-benzimidazol-2-one.